Comparative Pharmacology
Head-to-head clinical analysis: PROLIXIN DECANOATE versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROLIXIN DECANOATE versus QUIDE.
PROLIXIN DECANOATE vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic that blocks dopamine D1 and D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways, with higher affinity for D2 receptors. It also exhibits alpha-adrenergic blocking and anticholinergic activity.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
Fluphenazine decanoate initial dose 12.5-25 mg IM or SC every 1-4 weeks; maintenance dose 12.5-50 mg every 2-4 weeks.
5 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life approximately 14 days (range 6-25 days) after intramuscular injection, reflecting slow release from the oily depot; allows for every 2-4 week dosing.
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Renal (approximately 50% as conjugated metabolites, <1% unchanged) and fecal (approximately 30%, primarily via bile).
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic
Antipsychotic